文献速递妇科

远处转移性子宫内膜癌的基因组图谱

The genomic landscape of distant metastatic endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2025-03-12

该研究对2015年4月至2020年6月间接受临床 panel 测序的1888例病例中的远处转移性子宫内膜癌(EC)进行基因组分析,并与711例原发EC比较。远处转移EC(n=137)以CN-high/TP53异常(42%)或CN-low/NSMP(39%)分子亚型最常见,染色体不稳定性显著高于原发EC(p<0.0001),而临床可干预变异显著较少(27% vs 37%原发;p=0.025)。作者认为需利用转移EC的遗传差异开发靶向治疗策略。

要点

  • 远处转移EC以CN-high/TP53异常(42%)和CN-low/NSMP(39%)亚型为主。
  • 转移EC染色体不稳定性显著高于原发EC(p<0.0001)。
  • 转移EC临床可干预变异显著少于原发EC(27% vs 37%;p=0.025)。

核心结论

  • 远处转移性EC更常见染色体不稳定,但较少表现为超突变表型;作者认为需利用转移EC的遗传差异开发靶向治疗策略。

研究设计与样本

  • 研究纳入2015年4月至2020年6月间接受临床 panel 测序的1888例病例中的远处转移性EC,并与711例原发EC比较基因组图谱、受累通路和可干预变异。
  • 连续变量采用Wilcoxon检验,分类变量采用Fisher精确检验,p值经多重假设检验校正。

主要发现

  • 远处转移EC(n=137)部位包括肺(n=66,48%)、肝(n=21,15%)、软组织(n=15,11%)、远处淋巴结(n=15,11%)、胃肠道(n=10,7%)、中枢神经系统(n=5,4%)、骨(n=4,3%)和泌尿系统(n=1,1%)。
  • 远处转移EC分子亚型分布为CN-high/TP53异常42%、CN-low/NSMP 39%、MSI-high/MMR缺陷18%、POLE 1%。
  • 远处转移EC在各分子亚型中染色体不稳定性均显著高于原发EC(p<0.0001)。
  • CTNNB1突变在远处转移CN-low/NSMP和MSI-high/MMR缺陷亚型中较原发EC更常见(q<0.1)。
  • 临床可干预变异在转移EC中显著较少(27% vs 37%原发;p=0.025)。

关键数值与推荐

  • 远处转移EC分子亚型:CN-high/TP53异常42%,CN-low/NSMP 39%,MSI-high/MMR缺陷18%,POLE 1%。
  • 临床可干预变异:转移EC 27% vs 原发EC 37%(p=0.025)。
  • 染色体不稳定性在转移EC中显著高于原发EC(p<0.0001)。
  • CTNNB1突变在转移CN-low/NSMP和MSI-high/MMR缺陷亚型中较原发EC更常见(q<0.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The molecular underpinnings of primary treatment-naïve endometrial carcinoma (EC) are well described. Here we sought to characterize the genomic landscape of distant metastatic EC. METHODS: Distant metastatic ECs from a total of 1888 cases subjected to a clinical panel sequencing between 4/2015 and 6/2020 were identified, and their genomic profiles, affected pathways and actionable alterations were compared to those of 711 primary ECs. Wilcoxon and Fisher's exact tests were used for continuous and categorical variables, respectively, and p-values adjusted for multiple hypothesis-testing. RESULTS: Distant EC metastases (n = 137) of the lung (n = 66, 48 %), liver (n = 21, 15 %), soft tissue (n = 15, 11 %), distant lymph nodes (n = 15, 11 %), gastrointestinal tract (n = 10, 7 %), central nervous system (n = 5, 4 %), bone (n = 4, 3 %), and renal system (n = 1, 1 %) were included. Distant EC metastases were most commonly of copy number (CN)-high/TP53 abnormal (42 %) or CN-low/no specific molecular profile (NSMP) (39 %) molecular subtype; 18 % were microsatellite instability (MSI)-high/mismatch repair (MMR)-deficient and 1 % were of POLE molecular subtype. Distant EC metastases were significantly more chromosomally unstable compared to primary ECs across molecular subtypes (p < 0.0001). CTNNB1 mutations were more prevalent in distant CN-low/NSMP and MSI-high/MMR-deficient metastases compared to primary ECs (q < 0.1). Clinically actionable alterations were significantly less common in metastatic ECs (27 % vs 37 % primary; p = 0.025). PI3K, p53 and epigenetic pathways were the most altered pathways among all anatomic sites. CONCLUSIONS: Distant metastatic ECs are more frequently chromosomally unstable but less commonly exhibit hypermutator phenotypes. Exploitation of genetic differences of metastatic EC is warranted for targeted treatment strategy development.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Zammarrelli WA, Nandakumar S, Kertowidjojo E, et al. The genomic landscape of distant metastatic endometrial cancer. Gynecol Oncol. 2025. PMID: 40081112. doi:10.1016/j.ygyno.2025.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。